Cantor Fitzgerald analyst Steven Halper upgraded Humana to Overweight from Neutral and raised his price target for the shares to $345 from $300. The company's Louisiana Medicaid contract award demonstrates its success outside Medicare, Halper tells investors in a research note. Further, the analyst believes Humana's investments in population health management and social determinants of health will accelerate its growth over time.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
Affirms FY 2024 Insurance segment benefit ratio of approximately 90%. Raises 2024 individual Medicare Advantage annual membership growth by 50,000 to now anticipate annual growth of approximately 150,000, or 2.8%.